PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
- 1 November 2017
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 86, 28-36
- https://doi.org/10.1016/j.ejca.2017.08.025
Abstract
No abstract availableFunding Information
- French Health Ministry (PHRC09_24-007)
- SIRIC (INCa-DGOS-INSERM 6038)
This publication has 28 references indexed in Scilit:
- PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast CancerJournal of Clinical Oncology, 2015
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831Journal of Clinical Oncology, 2014
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerThe New England Journal of Medicine, 2012
- Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 TherapyClinical Cancer Research, 2012
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerThe New England Journal of Medicine, 2012
- A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast CancerCancer Cell, 2007
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast CancerThe New England Journal of Medicine, 2006
- Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial CellsCancer Research, 2005
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2The New England Journal of Medicine, 2001
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987